Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children under 18 years old who have been diagnosed with type 1 diabetes and are being seen at the University Hospital of Saint-Etienne
- Children under 18 years old without diabetes or nerve-related conditions who are being included as a comparison group, matched by age (within 6 months) and sex, and who have not had anaesthesia in the 2 months before the study recording, and are not taking heart medications such as beta-blockers or anti-arrhythmic drugs
- Families who are members of, or covered by, the French Social Security system
Who may not be able to join:
- Children who have had a diabetes diagnosis for less than 5 years at the time of joining the trial
- Children who have a condition that affects the brain or brainstem
- Children who have a serious heart or breathing condition, or who are currently receiving treatment for a heart condition (such as heart rhythm problems)
- Children or parents who do not speak French, or who are not French residents covered by the French Social Security system
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (0)4 77 82 82 42
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
HF ECG index value
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.